BRAK LABS Peptide research, plainly written

documented protocols

CJC-1295 without DAC: what is documented about dosing

No study of this compound has been published, so no figure below comes from one. This page explains what that means rather than filling the gap.

Last Reviewed Editorial policy Methodology

What would normally go here is what a study administered. No study of this compound exists to have administered anything.

Not medical advice

This page reports what has been documented about a compound. It is not medical advice, not a diagnosis, not a dosing protocol, and not a recommendation to obtain or use anything described here. Talk to a licensed clinician about anything concerning your health. Read the full disclaimer.

Reviewed against editorial standards Updated

What this page reports, and what it does not

We report what has been documented. We do not prescribe what should be done.

Nothing here is a dosing recommendation. Statements about dosing reflect community and research reports only.

No trial established an amount of CJC-1295 without DAC for a person. Most of the rows below record what a published study gave to its animals or its cells, in the model that study built, with the species and the route named on the line. One row records that other figures circulate in community write-ups, and that this site does not republish them. Nothing here is a protocol, nothing here is scaled for a person, and this site publishes no preparation steps, no administration technique and no equipment. The reasoning is in the editorial policy.

Commonly cited protocols (extrapolated, not validated)

What published studies gave, in which species and by which route, and what circulates elsewhere. The source class is named on every row, and none of it is a clinical protocol
StudyWhat was givenFrequencyDurationNotes
Any study of this compoundNothing documentedNothing documentedNothing documentedNo registered or published study exists under this name
The linked version's trialsAmounts stated per kilogram in the source papersSingle, then weekly or every two weeks28 and 49 daysA different product. Its trials measured hormone concentrations, not outcomes
The blends it is usually sold inNothing documentedNothing documentedNothing documentedNo published study tested this compound combined with anything

Schedules for this compound circulate in detail, usually built by reasoning from a half-life. There are two half-lives available to reason from, one belonging to the linked version and one to sermorelin, and this compound is neither of them.

The blend problem compounds it. This compound is most often sold combined with a growth hormone secretagogue, and no published study has tested that combination, so even a figure correct for one component would say nothing about what the pair does.

Commonly cited protocols (extrapolated, not validated) exist for this compound, including in a peer-reviewed 2026 review that documents them as a clinical phenomenon rather than endorsing them. This site does not reproduce them as guidance.

Nothing here is a dosing recommendation. Talk to a licensed clinician about anything concerning your health.

Our takeThere is no documented figure for this compound from any study of it, and the two half-lives available to extrapolate from belong to the two molecules it sits between.,Talk to a licensed clinician about anything concerning your health.

Main routes people compare

Injection under the skin

The route this compound is sold for. No published study has measured what it does or where it goes by this route or any other.

In a blend with a second compound

The commonest way it is sold, most often with ipamorelin. No published study tested this compound in a blend, so nothing on this page describes what a blend does, and a result attributed to one cannot be assigned to either component.

What is said about cycle length and timing

No cycle length appears anywhere in the published record for this compound, because no study of it has ever been run to establish one.

Talk to a licensed clinician about anything concerning your health.

What has been measured about safety

A reader weighing what other people report giving usually wants the other half of the record next. What has been measured about CJC-1295 without DAC, and what has never been studied reports what has actually been measured, in what system and over what period, and the questions no published study has put.

Frequently asked questions

What is the half-life of this version?

No published study has measured it. The figure usually quoted, 5.8 to 8.1 days, belongs to the version with the albumin-binding linker, and that linker is what produced it.

Where do the schedules in circulation come from?

From reasoning off a half-life belonging to a different product, either the linked version or sermorelin. This site does not reproduce them as guidance.

Does the blend change anything?

No published study tested this compound in any blend, so nothing on the record describes what a combination does.

References

  1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. PMID 16352683 DOI 10.1210/jc.2005-1536
  2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006. PMID 17018654 DOI 10.1210/jc.2006-1702
  3. Van Hout MC, Hearne E. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Subst Use Misuse. 2016. PMID 26771670 DOI 10.3109/10826084.2015.1082595
  4. Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, RuchaŁa M. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026. PMID 42395176 DOI 10.3389/fendo.2026.1822475
  5. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. PMID 41966639 DOI 10.1007/s40279-026-02437-0
  6. Villegas Meza AD, Nocek M, Mitchell BC, Lizarraga M, DeFoor MT, Ruzbarsky JJ, Huard J, Philippon MJ. Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications. JBJS Rev. 2026. PMID 42160466 DOI 10.2106/JBJS.RVW.26.00027
  7. Janvier S, Cheyns K, Canfyn M, Goscinny S, De Spiegeleer B, Vanhee C, Deconinck E. Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market. Talanta. 2018. PMID 30029448 DOI 10.1016/j.talanta.2018.06.023
  8. Knoop A, Thomas A, Fichant E, Delahaut P, Schänzer W, Thevis M. Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS. Anal Bioanal Chem. 2016. PMID 26879649 DOI 10.1007/s00216-016-9377-3
  9. ClinicalTrials.gov. Registry sweep for CJC-1295, CJC 1295, CJC1295, modified GRF 1-29, drug affinity complex GHRH, tetrasubstituted GHRH analog and ConjuChem GHRH, plus a sponsor query for ConjuChem, run through the v2 API on 23 August 2026. Exactly one record names the compound in its interventions, NCT00267527, and that record identifies its intervention only as CJC 1295 with no description. No registration exists under the modified GRF name or under any name identifying the version without the albumin-binding linker. ClinicalTrials.gov. 2026. ClinicalTrials.gov
  10. ClinicalTrials.gov. NCT00267527, study ID GH100-013: a multicenter, randomized, placebo-controlled, double-blind phase 2 study of CJC 1295 administered for 12 weeks in HIV infected patients with HIV associated visceral obesity, sponsored by ConjuChem, listed enrolment 120. Recorded as TERMINATED with the whyStopped field EMPTY, no results posted, no primary outcome measures listed, and no update since 12 October 2006. Read through the v2 API on 23 August 2026. ClinicalTrials.gov. 2026. NCT00267527
  11. US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. The category 2 table carries the row CJC-1295, reading in full: compounded drugs containing CJC-1295 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to for peptide-related impurities and API characterization; FDA has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction; available clinical data are limited. The entry names the compound and does not distinguish the two products sold under that name. Page content current as of 22 April 2026, fetched with a browser user agent and read on 23 August 2026. FDA human drug compounding. 2026. FDA category 2 list
  12. World Anti-Doping Agency. The 2026 Prohibited List, international standard, effective 1 January 2026. Section S2.2.4 names CJC-1295 on the list's own face, alongside ipamorelin, ibutamoren, examorelin, GHRP-2, GHRP-6, sermorelin and tesamorelin. S2 substances are prohibited at all times. Retrieved by hand and read back on 9 August 2026; the URL serves zero bytes to automation and is ledgered in tools/unverified-sources.json. World Anti-Doping Agency. 2026. WADA 2026 Prohibited List
  13. US Food and Drug Administration. Drugs@FDA approved drug products, queried through the openFDA drugsfda endpoint on 23 August 2026 for CJC-1295 and CJC 1295 across the generic name and brand name fields. Both queries returned NOT_FOUND: there is no approved US application under either spelling. openFDA. 2026. openFDA drugsfda
  14. US National Library of Medicine. PubMed, searched for CJC-1295 and CJC 1295 on 23 August 2026. Both searches return the same set. Three published human studies carry the name, PMID 16352683, PMID 17018654 and PMID 19386527, and all three used the version with the albumin-binding linker. No published human study of the version without that linker was located under any of its names. PubMed. 2026. Source document